Skip to content

Korea
World
Technology
Business
Sports
Entertainment
Health

Korea
World
Technology
Business
Sports
Entertainment
Health

NeoImuntech

Neo-Imuntech, solid cancer’NT-I7+Kitruda’ combined use “Phase 2 started”

Neo-Imuntech, solid cancer’NT-I7+Kitruda’ combined use “Phase 2 started”

Neo-Imuntech, first administration of NT-I7 and Kitruda combined solid cancer treatment for patients in phase 2 clinical trials

Neo-Imuntech confirms public offering price of 7500 won… Subscription on March 4-5

Neo-Imuntech confirms public offering price of 7500 won… Subscription on March 4-5

Neo-Imuntech public offering price of 7500 won confirmed… Institutional Investor Demand Forecast Competition 1374 to 1

Neo-Imuntech public offering price of 7500 won confirmed… Institutional Investor Demand Forecast Competition 1374 to 1

Neo-Imuntech public offering price of 7500 won confirmed… Raised 112.5 billion won

Neo-Imuntech public offering price of 7500 won confirmed… Raised 112.5 billion won

Neo-Imuntech KOSDAQ listing stock report submission… Public offering of up to 96 billion won

Neo-Imuntech KOSDAQ listing stock report submission… Public offering of up to 96 billion won

Neo-Imuntech passes preliminary examination for listing on KOSDAQ.. “Listed early next year”

Neo-Imuntech passes preliminary examination for listing on KOSDAQ.. “Listed early next year”

footer

Contact Us
Sitemap
News-Sitemap

© 2025 Aju.News/en